4,901 trials
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Leber's Hereditary Optic Neuropathy
Primary: Number of Treatment Related Adverse Events — 1; 1; 1; 5 Participants
Cardiovascular Diseases
Primary: Step Counts — 48770 steps
Sepsis
Primary: Imipenem Clearance — 15.21 Liters per hour
Tobacco Use Disorder · Tobacco Smoking
Primary: Distribution Volume (VT) as Determined by [18F]-ASEM PET Scan — 22.640; 21.588; 22.226; 17.431 mL/cm^3
Sepsis
Primary: Imipenem Clearance — 17.31 L/h
Healthy Volunteer Study
Primary: Plasma Oxytocin Concentration 2 Minutes After Infusion Initiated — 105 picograms/ml of oxytocin
Alcohol Drinking
Primary: Abnormal Labs and Adverse Events — 9; 8; 0; 0 Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-227 — 464.4; 190.9; 370.0 nanogram per milliliter (ng/mL)
Opioid Overdose
Primary: Maximum Plasma Concentration (Cmax) — 10.8; 18.9; 22.2 ng/ml
Eczema · Atopic Dermatitis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0 — 11 Participants
Intracranial Pathology
Primary: Number of Consented Patients — 40 Participants
Schizophrenia
Primary: Maximum Plasma Concentration (Cmax) of OPC-34712 Following Single Oral Administration of 24 mg and 48 mg QW Formulation or 2 mg Conventional Tablet in Cohrt1 — 25.37…
Breast Cancer
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) With Severity Determined as Per National Cancer Institute Common Terminology Criteria for Adverse…